Defects in the Fanconi anemia pathway and chromatid cohesion in head and neck cancer

Cancer Research

Volumn 75, Issue 17, 2015, Pages 3543-3553

  Stoepker, Chantal ^a   Ameziane, Najim ^a   Van Der Lelij, Petra ^a   Kooi, Irsan E ^a   Oostra, Anneke B ^a   Rooimans, Martin A ^a   Van Mil, Saskia E ^a   Brink, Arjen ^a   Dietrich, Ralf ^b   Balk, Jesper A ^a   Ylstra, Bauke ^a   Joenje, Hans ^a   Feller, Stephan M ^c,d   Brakenhoff, Ruud H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b German Fanconi Anemia Support Group and Research Fund   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL LINE; CHROMATID; CHROMOSOMAL INSTABILITY; CHROMOSOME BREAKAGE; CONTROLLED STUDY; DNA CROSS LINKING; DNA REPAIR; FANCF GENE; FANCM GENE; FANCONI ANEMIA; FEMALE; GENETIC LINKAGE; GENOMIC INSTABILITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; MALE; ONCOGENE; PDS5A GENE; PHENOTYPE; PRIORITY JOURNAL; SOMATIC MUTATION; STAG2 GENE; CANCER STAGING; DNA DAMAGE; GENETICS; HEAD AND NECK TUMOR; MUTATION; PATHOLOGY; SISTER CHROMATID EXCHANGE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CHROMATIDS; CHROMOSOMAL INSTABILITY; DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MUTATION; NEOPLASM STAGING; SISTER CHROMATID EXCHANGE;

EID: 84942914230     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0528     Document Type: Article

References (50)

1. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
2. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010;11:220-8.
3. McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep 2012;13:528-38.
4. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res 2009;668: 4-10.
5. Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003;129: 106-12.
6. Kottemann MC, Smogorzewska A. Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 2013;493:356-63.
7. Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet 2013;92:800-6.
8. Oostra AB, Nieuwint AWM, Joenje H, de Winter JP. Diagnosis of fanconi anemia: chromosomal breakage analysis. Anemia 2012;2012:238731.
9. Sasaki MS, Tonomura A. A high susceptibility of Fanconi's anemia to chromosome breakage by DNA cross-linking agents. Cancer Res 1973;33: 1829-36.
10. Auerbach AD, Wolman SR. Susceptibility of Fanconi's anaemia fibroblasts to chromosome damage by carcinogens. Nature 1976;261:494-6.
11. Langevin F, Crossan GP, Rosado IV, ArendsMJ, Patel KJ. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature 2011; 475:53-8.
12. Van den Berg DJ, Francke U. Sensitivity of Roberts syndrome cells to gamma radiation, mitomycin C, and protein synthesis inhibitors. Somat Cell Mol Genet 1993;19:377-92.
13. Van der Lelij P, Chrzanowska KH, Godthelp BC, Rooimans MA, Oostra AB, Stumm M, et al. Warsaw breakage syndrome, a cohesinopathy associated with mutations in the XPD helicase family member DDX11/ChlR1. Am J Hum Genet 2010;86:262-6.
14. Van der Lelij P, Oostra AB, Rooimans MA, Joenje H, de Winter JP. Diagnostic overlap between fanconi anemia and the cohesinopathies: Roberts syndrome and warsaw breakage syndrome. Anemia 2010;2010: 565268.
15. Peters J-M, Nishiyama T. Sister chromatid cohesion. Cold Spring Harb Perspect Biol 2012;4: pii: a011130. doi.
16. Valeri A, Martínez S, Casado JA, Bueren JA. Fanconi anaemia: from a monogenic disease to sporadic cancer. Clin Transl Oncol 2011;13:215-21.
17. Marsit CJ, Liu M, Nelson HH, Posner M, Suzuki M, Kelsey KT. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 2004;23:1000-4.
18. Ameziane N, Chen F, Leemans CR, Brakenhoff RH, Joenje H. No evidence for FANCF gene silencing in head-and-neck squamous cell carcinomas. Cell Oncol 2009;31:53-6.
19. Hermsen MA, Joenje H, Arwert F, Welters MJ, Braakhuis BJ, Bagnay M, et al. Centromeric breakage as amajor cause of cytogenetic abnormalities in oral squamous cell carcinoma. Genes Chromosomes Cancer 1996;15:1-9.
20. Van Zeeburg HJT, Snijders PJF, Pals G, Hermsen MAJA, Rooimans MA, Bagby G, et al. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients. Cancer Res 2005; 65:1271-6.
21. Martens-de Kemp SR, Dalm SU, Wijnolts FMJ, Brink A, Honeywell RJ, PetersGJ, et al. DNA-bound platinumis themajor determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS One 2013;8: e61555.
22. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007;29:163-88.
23. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010;32:417-26.
24. Wu Z, Doondeea JB, Gholami AM, Janning MC, Lemeer S, Kramer K, et al. Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Mol Cell Proteomics 2011;10:M111.011635.
25. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJL, et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol 2008;30:299-306.
26. Knies K, Schuster B, Ameziane N, Rooimans M, Bettecken T, de Winter J, et al. Genotyping of fanconi anemia patients by whole exome sequencing: advantages and challenges. PLoS One 2012;7:e52648.
27. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science 2011;333:1039-43.
28. Grénman R, Carey TE, McClatchey KD, Wagner JG, Pekkola-Heino K, Schwartz DR, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer 1991;67:2741-7.
29. Seow HA, Penketh PG, Baumann RP, Sartorelli AC. Bioactivation and resistance to mitomycin C. Methods Enzymol 2004;382:221-33.
30. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7:573-84.
31. Vega H, Waisfisz Q, Gordillo M, Sakai N, Yanagihara I, Yamada M, et al. Roberts syndrome is caused by mutations in ESCO2, a human homolog of yeast ECO1 that is essential for the establishment of sister chromatid cohesion. Nat Genet 2005;37:468-70.
32. Van Der Heijden MS, Brody JR, Kern SE. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot. Cancer Biol Ther 2004;3:534-7.
33. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
34. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333: 1154-7.
35. Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
36. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey CS, et al. A polymorphic stop codon in BRCA2. Nat Genet 1996;14:253-4.
37. Kuznetsov SG, Liu P, Sharan SK. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med 2008;14:875-81.
38. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 2005;434:913-7.
39. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
40. Yuan SS, Lee SY, ChenG, Song M, Tomlinson GE, Lee EY. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999;59:3547-51.
41. Castella M, Pujol R, Callén E, Trujillo JP, Casado JA, Gille H, et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood 2011;117:3759-69.
42. Barber TD, McManus K, Yuen KWY, Reis M, Parmigiani G, Shen D, et al. Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci U S A 2008;105:3443-8.
43. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 2013;45:1459-63.
44. Solomon DA, Kim J-S, Bondaruk J, Shariat SF, Wang Z-F, Elkahloun AG, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 2013;45:1428-30.
45. Kon A, Shih L-Y, Minamino M, Sanada M, Shiraishi Y, Nagata Y, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013;45:1232-7.
46. Thol F, Bollin R, Gehlhaar M, Walter C, Dugas M, Suchanek KJ, et al. Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood 2014;123:914-20.
47. VanHarn T, Foijer F, van VugtM, Banerjee R, Yang F, Oostra A, et al. Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. Genes Dev 2010;24:1377-88.
48. Manning AL, Longworth MS, Dyson NJ. Loss of pRB causes centromere dysfunction and chromosomal instability. Genes Dev 2010;24:1364-76.
49. Manning AL, Yazinski SA, Nicolay B, Bryll A, Zou L, Dyson NJ. Suppression of genome instability in pRB-deficient cells by enhancement of chromosome cohesion. Mol Cell 2014;53:993-1004.
50. Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJM, Brakenhoff RH. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol 2013; 49:560-6.